International Journal of Breast Cancer最新文献

{"title":"Advancements in Nanoparticle-Based Therapies for Breast Cancer: Current Trends and Future Prospects.","authors":"Sina M Matalqah, Laila Mahmoud Matalqah, Abdel Rahman Al Tawaha, Arun Karnwal, Lujain Radaideh, Asem Mhaidat, Natalia Nesterova","doi":"10.1155/ijbc/1986406","DOIUrl":"10.1155/ijbc/1986406","url":null,"abstract":"<p><p>Breast cancer, one of the leading cancer types, directly contributes to cancer-related mortality, but new therapies are required to improve treatment efficiency. Nanoparticle-based strategies have already introduced the most radical advances in this regard, from their first formulation through their development to the next generation as promising candidates. The present review provides an overview of nanoparticle-based strategies in breast cancer, their development, and their state of the art. The review addresses the diverse formulation of nanoparticles, including liposomes, dendrimers, and metallic nanoparticles, as well as their respective roles in drug delivery: bioavailability, focused therapeutic intervention, and lower systemic toxicity. This review covers studies on the engineering of nanoparticles for improved drug delivery, including cancer-targeted delivery to tumors and optimization within the tumor microenvironment. Additionally, new nanosized drugs may also be utilized for novel modification of nanoparticle composition for combination therapeutics, which allows pharmacological agents to enter the tumor microenvironment by combined treatment with diverse types of other agents, to provide a synergistic, effective treatment in real time, in addition to real-time monitoring. Stimuli-responsive nanoparticles, which release the drug according to the appropriate stimulus signal to provide greater accuracy and regulation in delivering the drug, are also under investigation. This review notes trends in personalized nanomedicine and nanoparticle-mediated immunotherapy that target personalized patient and immune responses, among others. Other exciting areas for nanoparticle research include AI-based optimal design and sustainable biodegradable materials aimed at maintaining nanoparticle safety. Nanoparticle-based therapies are a unique new frontier in breast cancer therapy. They have considerable clinical potential, offer promise for patient-specific treatment, and warrant further investigation in breast cancer, particularly in advanced targeting mechanisms, multifunctional approaches, and individualized interventions.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"1986406"},"PeriodicalIF":1.9,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148473448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Breast Cancer Preventive Behaviors Among Female Health Ambassadors in Khoy: An Analysis Based on the Protection Motivation Theory.","authors":"Morad Ali Zareipour, Leila Mokhtari, Rahim Sharafkhani, Hamideh Safaralizadeh, Mohammad Saeed Jadgal","doi":"10.1155/ijbc/7656595","DOIUrl":"10.1155/ijbc/7656595","url":null,"abstract":"<p><strong>Introduction and objective: </strong>Breast cancer is the most prevalent malignancy among Iranian women, and early detection plays a pivotal role in reducing mortality. This study was aimed at investigating factors associated with breast cancer preventive behaviors among female health ambassadors in Khoy, using the protection motivation theory as the theoretical framework.</p><p><strong>Methods: </strong>This cross-sectional analytical study was conducted among 160 female health ambassadors in Khoy in 2023. Data were collected using a standardized questionnaire based on protection motivation theory constructs, including knowledge, perceived susceptibility, perceived severity, self-efficacy, response efficacy, response costs, fear, and protection motivation. Data were analyzed using Stata Version 18, applying backward linear regression to identify factors associated with breast cancer preventive behaviors.</p><p><strong>Results: </strong>Among demographic variables, university education (<i>B</i> = 2.05, <i>p</i> = 0.008) and employment status (<i>B</i> = 1.58, <i>p</i> = 0.002) were significantly associated with breast cancer preventive behaviors. Among protection motivation theory constructs, fear (<i>B</i> = 0.32, <i>p</i> < 0.001) showed the strongest association, followed by protection motivation (<i>B</i> = 0.25, <i>p</i> = 0.007), knowledge (<i>B</i> = 0.10, <i>p</i> = 0.002), and perceived severity (<i>B</i> = 0.09, <i>p</i> < 0.001); all variables were significantly associated with preventive behaviors. The final model explained 65.6% of the variance in preventive behaviors (<i>R</i> ² = 0.656, adjusted <i>R</i> ² = 0.639, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The findings support the applicability of the protection motivation theory in explaining breast cancer preventive behaviors among female health ambassadors in Khoy City. Theory-based educational interventions, potentially tailored for similar demographic groups characterized by lower education levels and unemployment, may help strengthen preventive practices. However, due to the cross-sectional design of this study and its focus on a specific population in a single city, the observed relationships should be interpreted strictly as associations rather than causal effects, and these results cannot be generalized to all Iranian women. These findings highlight the potential role of community health educators in developing targeted community-based prevention programs for specific at-risk populations.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"7656595"},"PeriodicalIF":1.9,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Mammographic Density in Younger Women and Its Implications for Breast Cancer Subtypes.","authors":"Sariningsih Hikmawati, Kardinah, Rizky Ifandriani Putri, Vincent Laiman, Intan Mupangat, Rozan Muhammad Irfan, Zannuba Arifah Noor, Putri Noviantika Laskarsantri, Laksmitha Saktiono Safitri, Artanto Wahyono, Didik Setyo Heriyanto, Lina Choridah","doi":"10.1155/ijbc/8401844","DOIUrl":"10.1155/ijbc/8401844","url":null,"abstract":"<p><strong>Background: </strong>High breast density is commonly observed in younger breast cancer patients (<45 years), and Asian women generally have dense breasts even beyond the age of 45 years. Its relationship with breast cancer subtypes and its profile remains unclear. This study is aimed at exploring the association between mammographic density and breast cancer molecular subtypes.</p><p><strong>Methods: </strong>A cross-sectional study evaluating mammographic density based on the 2013 BI-RADS classification among breast cancer patients at Dharmais Cancer Hospital between 2021 and 2023 was conducted. Clinicopathological variables-including histological subtype, tumor grade, ER, PR, HER2 status, Ki-67 index, and molecular subtypes by immunohistochemistry-were analyzed.</p><p><strong>Results: </strong>High breast density (BI-RADS C and D) was observed in 69% of patients, with Category C being the most common (57.1%). Invasive ductal carcinoma of no special type was the most prevalent and 47.2% of tumors were high grade. Most tumors were ER-negative (67.1%), PR-negative (59.6%), and HER2 0 (54.0%), with high Ki-67 index in 70.2% of cases. Age was associated with breast Density C and D and TNBC molecular subtype (<i>p</i> < 0.05). HER2, Ki-67, and molecular subtype were negatively correlated with ER (<i>r</i> = -0.217, <i>r</i> = -0.283, and <i>r</i> = -0.851, respectively; <i>p</i> < 0.05) and with PR (<i>r</i> = -0.169, <i>r</i> = -0.287, and <i>r</i> = -0.840, respectively; <i>p</i> < 0.05). Conversely, HER2 and Ki-67 expressions were positively correlated with more aggressive molecular subtypes (<i>r</i> = 0.307 and <i>r</i> = 0.354, respectively; <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Younger breast cancer patients were associated with higher breast density and more aggressive tumor subtypes, which correlated with HER2 and Ki-67 expressions in breast cancer. These underscore the relevance of age-related biological factors in shaping breast cancer characteristics. However, among Indonesian women over 45 years old, the proportion of high breast density remains remarkably high (65.6%), suggesting that factors beyond age-such as genetic, hormonal, or lifestyle influences-may contribute to the persistence of dense breast tissue in this population.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"8401844"},"PeriodicalIF":1.9,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Disease-Free Survival (DFS) and Overall Survival (OS) Rates in Breast Cancer Patients: Axillary Lymph Node Dissection (ALND) Versus Sentinel Lymph Node Biopsy (SLNB).","authors":"Bahar Amiri, Mahta Mellat Ardakani, Ali Pajouhi, Atieh Akbari, Simin Farokhi, Mohammad Esmaeil Akbari, Samaneh Tahmasebi Ghorabi, Arian Karimi Rouzbahani, Mania Beiranvand","doi":"10.1155/ijbc/5039446","DOIUrl":"10.1155/ijbc/5039446","url":null,"abstract":"<p><strong>Background: </strong>Examining the survival rate in breast cancer patients serves as a metric for assessing and advancing various treatment modalities. In light of the significant incidence of breast cancer in Iran, this study is aimed at examining and comparing the disease-free survival (DFS) and overall survival (OS) rates among breast cancer patients who underwent axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SLNB).</p><p><strong>Patients and methods: </strong>This retrospective cohort research included 1071 patients at Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, from 1991 to 2021. The recurrence and survival rates of patients undergoing ALND and SLNB in both groups were examined and evaluated. The data were analyzed using SPSS statistical software using descriptive statistical techniques (percentage, frequency, mean, and standard deviation), Kaplan-Meier analysis, and Cox regression tests. A significance threshold of 0.05 is used.</p><p><strong>Results: </strong>The average OS among all patients was 18.08 ± 0.51. The average OS in the ALND group was 18.1 ± 0.53; in the SLNB group, it was 12.8 ± 0.39, which was insignificant (<i>p</i> < 0.05). The average DFS among all patients was 17.13 ± 0.51. The average DFS in the ALND group was 16.95 ± 0.54; in the SLNB group, it was 11.96 ± 0.3; the difference was insignificant (<i>p</i> = 0.11).</p><p><strong>Conclusion: </strong>OS and DFS in the ALND group were higher than in the SLNB group, but they were not statistically significant.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"5039446"},"PeriodicalIF":1.9,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Angiogenesis in Breast Cancer and Obesity: Unravelling the Connection.","authors":"Yolo O K Sikuza, Charlise Basson, Nanette Oberholzer, Melvin A Ambele","doi":"10.1155/ijbc/2364200","DOIUrl":"10.1155/ijbc/2364200","url":null,"abstract":"<p><p>Breast cancer remains one of the leading causes of cancer-related mortality amongst women worldwide, with rising incidence rates paralleling the global obesity epidemic. Obesity has been increasingly recognised as a risk factor for breast cancer, yet the molecular mechanisms underlying the association remain poorly understood. This review explores the role of angiogenesis as the central mechanism linking obesity to breast cancer progression. Angiogenesis is essential for both adipose tissue expansion and tumour growth. It is dysregulated in obesity and breast cancer, resulting in the formation of abnormal vasculature that perpetuates hypoxia and malignancy. Obesity contributes to this process through hypertrophic adipose tissue, altered adipokine profiles and elevated expression of proangiogenic factors, such as VEGF. These changes create a tumour microenvironment conducive to cancer progression, treatment resistance and poor clinical outcomes. Emerging evidence also implicates endothelial cells, pericytes and lipid metabolism in this interaction, suggesting novel therapeutic targets.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"2364200"},"PeriodicalIF":1.9,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of AC-T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis.","authors":"Mehrzad Mirzania, Fatemeh Anari, Seyed Amir Hossein Emami, Kamran Roudini, Mehdi Karimi, Kianmehr Saleh, Masoud Mortezazadeh, Ahmad Khajeh-Mehrizi","doi":"10.1155/ijbc/6630563","DOIUrl":"10.1155/ijbc/6630563","url":null,"abstract":"<p><strong>Purpose: </strong>Locally advanced breast cancer (LABC) remains a major therapeutic challenge, with neoadjuvant chemotherapy (NAC) serving as a cornerstone of management. However, direct evidence comparing the efficacy of sequential (AC-T) and concurrent (TAC) anthracycline-taxane regimens in real-world Middle Eastern populations remains scarce. This study is aimed at comparing the clinical outcomes of AC-T and TAC in Iranian women with LABC.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted among 118 patients with Stage III breast cancer treated at Tehran, Iran. Patients received either AC-T (doxorubicin/cyclophosphamide followed by paclitaxel; <i>n</i> = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; <i>n</i> = 48). Outcomes included pathological complete response (pCR), overall survival (OS), disease-free survival (DFS), distant recurrence-free survival (DRFS), and locoregional recurrence-free survival (LRFS).</p><p><strong>Results: </strong>Baseline demographic and clinical characteristics were comparable between groups. No significant difference in pCR rates was observed between the groups. The AC-T regimen showed higher, though nonsignificant, OS at 3, 5, and 10 years (90%, 82%, and 71%, respectively) compared with TAC (83%, 74%, and 57%). Conversely, TAC demonstrated significantly superior 10-year DRFS (62% vs. 45%, <i>p</i> = 0.019). DFS and LRFS were similar between regimens. Multivariable Cox regression analysis identified ER positivity as the only independent predictor of improved OS (HR = 0.42, 95% CI: 0.29-0.82, <i>p</i> = 0.012) and DFS (HR = 0.36, 95% CI: 0.18-0.73, <i>p</i> = 0.005), whereas the chemotherapy regimen was not independently associated with survival after adjustment for confounders.</p><p><strong>Conclusion: </strong>Both AC-T and TAC provided effective neoadjuvant control in LABC, with comparable survival outcomes. These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region-specific treatment strategies.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"6630563"},"PeriodicalIF":1.9,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Effectiveness of the Comprehensive Oncology Rehabilitation and Exercise (CORE) Clinical Workflow Algorithm on Health Outcomes During Nonmetastatic Breast Cancer Care.","authors":"Lea Haverbeck Simon, Carson Saviers-Steiger, Emily R Dunston, Susan L Zickmund, Pamela A Hansen, Cornelia M Ulrich, Paul C LaStayo, David Steinberg, Christopher S Noren, A'Lisha Finch, Leanne Seckinger, Emma Braun, Jonathan Chipman, Sonal Oza, Kirstyn E Brownson, Adriana M Coletta","doi":"10.1155/ijbc/8894250","DOIUrl":"10.1155/ijbc/8894250","url":null,"abstract":"<p><strong>Background: </strong>The Comprehensive Oncology Rehabilitation and Exercise (CORE) pilot trial aimed to test the feasibility and acceptability of a clinical workflow algorithm that integrated exercise and rehabilitation services from breast cancer diagnosis throughout the first 24 weeks of care. Here, we investigated the preliminary effectiveness of the CORE algorithm compared with standard of care (SOC) on changes in physical function, health-related quality of life (HRQoL), and exercise engagement in women newly diagnosed with Stage I-III breast cancer with plans for surgery as first-line treatment.</p><p><strong>Methods: </strong>Seventy-two women were randomly assigned in a 2:1 ratio to CORE or SOC. All participants completed study assessments at three time points that aligned with routine breast surgical oncology clinic visits: surgical consultation (i.e., baseline), postoperative, and 24 weeks postoperative. The following outcomes and associated assessments were carried out in the clinic: physical function: PROMIS physical function survey (primary function assessment), five-time chair stand, 10-m walk, back scratch, and QuickDASH survey; HRQoL: FACT-B survey; and exercise engagement: modified Godin physical activity survey (primary engagement assessment) and accelerometer wear for 1 week following each clinic visit.</p><p><strong>Results: </strong>Fifty-nine participants had evaluable data, with the majority having Stage I disease (83%), being primarily White (75%) and non-Hispanic (90%), and having a median age and BMI of 58 years and 26.0 kg/m², respectively. Mean difference in change in PROMIS physical function score from baseline to 24 weeks postoperative between CORE and SOC was not statistically significant (-1.86, 95% CI -6.02 to 2.3). A modest advantage in exercise engagement was observed in the CORE arm (Godin: 5.46, 95% CI -1.06 to 11.98; effect size: 0.36, 95% CI -0.07 to 0.78; accelerometry: median difference 12 min, bootstrapped 95% CI -37 to 40).</p><p><strong>Conclusion: </strong>The CORE clinical workflow algorithm demonstrates promise in improving exercise engagement. More work is needed in an adequately powered trial to confirm these findings and evaluate effectiveness on other outcomes.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04594473.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"8894250"},"PeriodicalIF":1.9,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13255010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Skin Toxicities After Ultrahypofractionated Versus Hypofractionated Postoperative Radiotherapy in Patients With Early Breast Cancer-A Single-Institution Clinical Study.","authors":"Gordana Petkovska, Ivica Ratosa, Valentina Bojovska Trajanovska, Marina Iljovska, Emilija Lazareva, Antonija Lazarevska, Violeta Klisarovska, Snezhana Smichkoska","doi":"10.1155/ijbc/3641929","DOIUrl":"10.1155/ijbc/3641929","url":null,"abstract":"<p><strong>Background: </strong>Real-world safety data from Southeastern Europe are limited for ultrahypofractionated (UHF) whole-breast irradiation (WBI). We aimed to evaluate acute skin toxicity with UHF versus hypofractionated (HF) postoperative radiation therapy in early breast cancer, following implementation of this fractionation regimen.</p><p><strong>Methods: </strong>This combined prospective-retrospective study included women aged ≥50 years following breast-conserving surgery (pT1-2, pN0-1, M0). The UHF cohort (prospective) received 26 Gy in 5 fractions over one week between 2023 and 2024. The control group consisted of retrospective data obtained from institutional records of patients who received WBI using a HF schedule of 40.5-42.6 Gy in 15-16 fractions over 3 weeks between 2015 and 2020. All patients were treated with 3D-CRT WBI without regional nodal irradiation or boost. Acute skin toxicity was graded by CTCAE v5.0 at end of treatment and at 4 and 12 weeks.</p><p><strong>Results: </strong>This study included 80 patients, with 40 in each group, with a mean age of 61.1 ± 6.6 years. Baseline clinicopathological characteristics were comparable, except for a slightly larger median tumor size in the UHF group (<i>p</i> = 0.037). At the end of radiation therapy, acute radiodermatitis occurred in 36 of 40 (90%) patients receiving UHF and in 38 of 40 (95%) patients receiving HF (p = 0.396). The grade distribution was comparable across the two groups (<i>p</i> = 0.53), and no grade ≥3 events were recorded. At 4 weeks, no adverse skin reactions were observed in patients receiving UHF, and by twelve weeks, no active radiodermatitis persisted in either group.</p><p><strong>Conclusions: </strong>UHF WBI (26 Gy/5 fractions) demonstrated comparable acute skin toxicity to standard HF regimens, supporting its safety and clinical feasibility in routine practice.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"3641929"},"PeriodicalIF":1.9,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148200621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning-Based Prediction of Breast Cancer in Women: Insights From Feature Selection of Clinical and Lifestyle Data.","authors":"Leila Allahqoli, Mohammad Hassan Behzadi, Seyedeh Zahra Aghamohammadi, Sevil Hakimi, Hamid Salehiniya, Arezoo Fallahi, Azam Rahmani, Zahra Shahabinia, Afrooz Mazidimoradi, Zohre Momenimovahed, Mohammadmatin Ghiyasvand","doi":"10.1155/ijbc/8510185","DOIUrl":"10.1155/ijbc/8510185","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study is aimed at developing and evaluating a machine learning-based model for breast cancer classification using integrated clinical, demographic, reproductive, and lifestyle data.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective machine learning framework was developed using data from a case-control study conducted in Tehran. The dataset included demographic, clinical, reproductive, lifestyle, and screening-related variables. Data preprocessing was performed within machine learning pipelines to ensure data quality and prevent data leakage. Duplicate records and noninformative variables were removed. Missing values were imputed using median values for numerical variables and the most frequent value for categorical variables. Categorical features were encoded appropriately, and Min-Max normalization was applied where required. Feature selection was conducted using mutual information (MI) and analysis of variance (ANOVA) within a stratified cross-validation framework. The data were split into training (80%) and test (20%) sets. Several supervised learning algorithms, including Gaussian Naive Bayes (GNB), K-nearest neighbors (KNN), decision tree (DT), random forest (RF), support vector machine (SVM), logistic regression (LR), and artificial neural network (ANN), were trained and evaluated. Model performance was assessed using accuracy, precision, recall (sensitivity), F1-score, and receiver operating characteristic-area under the curve (ROC-AUC), with stratified 5-fold cross-validation and final evaluation on an independent test set.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Significant differences were observed between breast cancer patients and healthy controls across multiple demographic and clinical variables. Patients were generally older and more likely to be widowed, belong to higher socioeconomic classes, and be housewives, whereas higher education levels and employment were more frequent among healthy individuals (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Reproductive factors, including age at first marriage and breastfeeding duration, also showed significant differences. Feature selection reduced 414 initial variables to 40 key predictors. The most influential features included genetic factors (BRCA1/2 mutations and family history), reproductive and hormonal characteristics (age at menarche, menopause, and infertility), lifestyle behaviors (dietary patterns and physical activity), anthropometric measures (BMI and weight at age 30), and screening-related variables (mammography, ultrasound, and biopsy). All models demonstrated strong and stable performance with minimal differences between cross-validation and test results, indicating good generalization. RF achieved the highest performance (accuracy: 0.9897, precision: 0.9946, recall: 0.9840, F1-score: 0.9892), followed by SVM and LR, whereas ANN showed the lowest overall performance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Machine learning models can effectively classify breast cancer using m","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"8510185"},"PeriodicalIF":1.9,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Postmastectomy Radiotherapy in Immediate Breast Reconstruction-Results From the iBRA-2 Cohort Study.","authors":"Tim Rattay, Adam Trickey, Rachel L O'Connell, Rajiv V Dave, Joanna Skillman, Nicola L P Barnes, Matthew D Gardiner, Chris Holcombe, Shelley Potter","doi":"10.1155/ijbc/5902426","DOIUrl":"10.1155/ijbc/5902426","url":null,"abstract":"<p><strong>Purpose: </strong>Long-term data indicate that postmastectomy radiotherapy (PMRT) is associated with improved overall survival in node-positive breast cancer patients. Immediate breast reconstruction (IBR) remains controversial in the context of planned PMRT, but rates of IBR are increasing. The aim of this study was to examine patterns of PMRT in patients undergoing mastectomy with or without IBR.</p><p><strong>Methods: </strong>Data were collected from 2526 patients enrolled in the iBRA-2 prospective cohort study undergoing 2606 mastectomies with and without IBR between 1 July 2016 and 31 December 2016. Patients were recruited consecutively at 71 centres across the United Kingdom (UK) and Ireland and at five international centres. Univariable and multivariable logistic regression models were used to explore associations between recommendation for PMRT and patient- and procedure-related factors.</p><p><strong>Results: </strong>Of 2590 breast procedures included in the analysis, 696 were implant-based, 105 pedicled-flap and 230 free-flap reconstructions, and 32.5% of implant-based, 34.3% of pedicled-flap and 35.7% of free-flap reconstructions were recommended for PMRT. PMRT recommendation by cancer stage was 21% for T1-2 N0, 65% for T1-2 N1 and 89% for T_any N2 and T3 N_any. In multivariable analyses, patients with invasive disease undergoing implant-only reconstruction, but not pedicled-flap or free-flap reconstruction, were less likely to be recommended for PMRT than those undergoing mastectomy alone. The likelihood of being recommended for PMRT differed by region.</p><p><strong>Conclusion: </strong>Although IBR was more likely to be performed for lower-stage cancers and in younger patients with fewer comorbidities, a third of patients undergoing IBR were recommended for PMRT. This adds to a growing body of evidence that IBR is becoming an acceptable option for women requiring PMRT. The study also highlighted regional variation in PMRT practice within the UK and Ireland, which merits further investigation.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2026 ","pages":"5902426"},"PeriodicalIF":1.9,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}